Genome-wide association studies (GWAS) have revealed that different diseases share susceptibility variants. Twelve singlenucleotide polymorphisms (SNPs) previously associated with different immune-mediated diseases in GWAS were genotyped in a Caucasian Spanish population of 2864 multiple sclerosis (MS) patients and 2930 controls. Three SNPs were found to be associated with MS: rs1678542 in KIF5A (P ¼ 0.001, odds ratio (OR) ¼ 1.13, 95% confidence interval (CI) ¼ 1.05-1.23); rs3184504 in SH2B3 (P ¼ 0.00001, OR ¼ 1.19, 95% CI ¼ 1.10-1.27) and rs763361 in CD226 (P ¼ 0.00007, OR ¼ 1.16, 95%CI ¼ 1.08-1.25). These variants have previously been associated with rheumatoid arthritis and type 1 diabetes. The SH2B3 polymorphism has additionally been associated with systemic lupus erythematosus. Our results, in addition to validating some of these loci as risk factors for MS, are consistent with shared genetic mechanisms underlying different immune-mediated diseases. These data may help to shape the contribution of each pathway to different disorders.
Introduction
Multiple sclerosis (MS, MIM 126200) is a chronic autoimmune disease of the central nervous system with a complex pathogenesis in which demyelination and neurodegeneration are the main contributors to disability. 1, 2 Prevalence and incidence rates in Spain are around 77/100 000 habitants and 5.3/100 000 habitants per year, respectively. 3 MS is estimated to affect over 2 million individuals worldwide, and is the most common central nervous system disease in young adults of developing countries. Although the etiology remains elusive, disease susceptibility is thought to be conferred by a combination of genetic and environmental factors. 4, 2 The disease shows familial clustering, and about onefifth of affected individuals have a family history of MS. Siblings to MS patients exhibit a 20-40 times higher relative risk of MS than the general population, and twin studies have revealed that a large proportion of family clustering can be attributed to shared genes. 5 Genetic studies in autoimmune diseases have for long supported a model in which the major risk factor resides in the HLA region. 2 However, recent application of genome-wide association studies (GWAS) to large sample sets have provided a convincing support for additional risk loci outside the HLA region, all with low-risk contribution to the disease. [6] [7] [8] It is relatively common that patients affected by one autoimmune disease suffer from another autoimmune disease, and that members of the same family suffer from different autoimmune diseases. For example, co-occurrence of type 1 diabetes (T1D), autoimmune thyroiditis (Graves' disease and Hashimoto's disease), rheumatoid arthritis (RA), celiac disease and MS has been observed. 9 In families with systemic lupus erythematosus (SLE), other autoimmune diseases, such as MS and RA, occur more frequently than in the general population. 10 Such observations suggest the presence of shared genes and involvement of common disease pathways, and are supported by a number of reports on genes that are associated with more than one autoimmune disease, such as PTPN22 in RA and SLE, 11 IRF5 in MS, 12 RA 13 and SLE, 14 and more recently IL2RA/CD25 in T1D 15 and MS, 16 though with a different risk allele. As GWAS constitute powerful tools to detect common genetic susceptibility variants in complex diseases, these screens have further revealed that different diseases share associated variants. 17 In fact, the variants associated in one disease are now routinely genotyped in related diseases, thus providing the rationale for the candidate gene approach that we have applied to MS in this study. As such, 12 candidate genes that have been identified recently in the GWAS published over the past 2 years and validated in different immune-mediated pathologies, such as RA, SLE, ankylosing spondylitis, psoriasis, T1D and MS, were selected and analyzed for their association in our cohort of MS patients and controls.
Results and discussion
In this work, we have shown for the first time an association of the rs1678542/KIF5A variant with MS in a Caucasian Spanish cohort comprising 2864 MS cases and 2930 controls (Table 1) , and confirmed the recently found associations of the rs763361/CD226 and rs3184504/ SH2B3 variants. For this study, we selected 12 singlenucleotide polymorphisms (SNPs); ). There were no statistically significant differences in the genotyping failure rate between the cases and controls for any of these markers. None of the markers deviated from Hardy-Weinberg equilibrium (HWE).
As shown in Table 2 , four SNPs were associated with MS. The strongest association corresponded to SNPs rs763361 in the CD226 gene (P ¼ 0.000069) and rs3184504 in the SH2B3 gene (P ¼ 0.000011). These two variants were first identified in a T1D 23 GWAS, but were, however, not detected as risk factors for MS in an association study of 14 500 SNPs carried out by the Wellcome Trust Case-Control Consortium in 1000 MS patients and 1500 controls (rs763361, P ¼ 0.09, odds ratio (OR) ¼ 1.1 (0.98-1.24); rs3184504, P ¼ 0.84, OR ¼ 1.012 (0.9-1.13)). 22 Subsequent candidate studies provided convincing evidence for association with MS 17, 25 (summarized in Table 3 ).
As illustrated in Figure 1 , a meta-analysis of our data was performed in combination with the results obtained for these two variants in the study of the International Multiple Sclerosis Genetics Consortium, 17 which includes five populations (Belgium, Norway, Sweden, UK and USA). Two other studies have also reported association of rs763361/CD226 with MS, 25, 26 however, because of some sample overlapping they were not included in our analysis. The overall effect estimates for the rs763361/CD226 and rs3184504/SH2B3 variants were statistically significant with combined ORs (95% confidence interval (CI)) of 1.14 (1.09-1.18) and 1.13 (1.08-1.17), respectively. Heterogeneity variance was estimated not to be significant for any of the polymorphisms (P ¼ 0.889 and P ¼ 0.526, respectively).
In addition to T1D, the rs763361/CD226 variant was also found to be associated with other autoimmune diseases such as RA 25 and Graves' disease. 25 Tag-SNP studies in this gene for T1D and MS suggest that rs763361/CD226, which is a non-synonymous SNP, Table 2 Summary of association results for multiple sclerosis case-control study Abbreviations: A4a, major4minor allele; AS, ankylosing spondylitis; BANK1, B cell scaffold protein with ankyrin repeats; BLK, B lymphoid tyrosine kinase; CCL21, chemokine (C-C motif) ligand 21; CD226, cluster of differentiation 226; CH, chromosome; CI, confidence interval; DS, disease firstly described to be associated with the corresponding SNP; ERAP1, endoplasmic reticulum aminopeptidase 1; FAM167A, family with sequence similarity 167, member A; HERC1, homologous to the E6-AP (UBE3A) carboxyl terminus; IL1A, interleukin-1a; Kif5A, kinesin family member 5; MS, multiple sclerosis; n, number of samples; OR, odds ratio for the risk allele originally reported; P BH ; P corrected with Benjamini-Hochberg; P, uncorrected P-value; PS, psoriasis; PTPN2, protein tyrosine phosphatase non-receptor type 2; RA, rheumatoid arthritis; ref., reference; SLE, systemic lupus erythematosus; STAT2, signal transducer and activator of transcription 2; SH2B3, SH2B adaptor protein 3; SNP, single-nucleotide polymorphism; STEAP1, six transmembrane epithelial antigen of the prostate 1; T1D, type 1 diabetes.
*Bold labels indicate significant associations. Departure from Hardy-Weinberg equilibrium (HWE) was tested using the Fisher's exact test. For individual SNP association analyses, genotype frequencies were assessed assuming an additive model (e.g., multiplicative allelic effect). Logistic regression models, adjusted for region, were used to estimate crude ORs and 95%CI. P-values were computed using a likelihood ratio test. Analysis was performed using the SNPassoc R package (Catalan Institute of Oncology; http://bioinfo.iconcologia.net/index.php?module=SNPassoc). 33 To avoid false-positive results due to multiple testing, and considering that the SNPs analyzed are not in complete linkage disequilibrium, we applied the Benjamini-Hochberg (BH) method. 34 Power was calculated for the effect detected in previous reports with different diseases at an a level of 0.05, assuming a multiplicative allelic effects model, and a sample number of 2864 cases and 2930 controls. Genotyping was performed using the MassARRAY SNP genotyping system (Sequenom 3595 John Hopkins Court, San Diego, CA, USA) according to the manufacturer's instructions at the Spanish National Genotyping Center's (CeGen, Santiago de Compostela). Two CEPH trios were genotyped as part of the quality control (QC) (CEPH, Na10830, Na10831, Na12147, Na10860, Na10861 and Na11984). The genotypes of these samples confirmed absence of Mendelian inconsistencies and corresponded with the ones deposited in HapMap. On the other hand, a 10% of random samples were subjected to re-genotyping. Final data were concordant with an average accuracy of 499.9%.
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Gly307Ser), could be the causal variant. 23, 25 This SNP might affect the expression and/or biological activity of CD226 by disruption of an exon splicing silencer sequence. The minor allele A maintains the sequence motif of an exon splicing silencer in the final 3 0 exon, whereas the G allele disrupts it. The allele A expression product is therefore likely to result in a putative CD226 isoform, acting either as a nonfunctional protein or as a protein with a novel function. This amino-acid substitution could alter the signaling cascade by affecting the two known phosphorylation sites at positions 322 and 329. 23 The identification of rs3184504/SH2B3 as a risk factor for T1D followed that of rs17696736, originally uncovered in a T1D GWAS. 27 The latter SNP was also found to be associated with SLE in a very large cohort (P ¼ 0.014, OR ¼ 1.08). 28 Both polymorphisms are located within a large (41.2 Mb) linkage disequilibrium block that contains several genes of possible functional relevance for The SH2B3 gene product (Lnk) is an adaptor protein expressed primarily in the lymphocytes and hematopoietic precursor cells. The possible role of the SH2B3 variant associated in these studies to different autoimmune diseases is at the moment undetermined, mainly because of the lack of knowledge on the functional role of the causal variant. However, the overexpression as well as the deficiency of this gene has consequences that could be of importance in the development of autoimmune diseases. SH4B3 overproduction in lymphoid precursors resulted in a reduction in the number of both B and T cells, whereas the lack of the SH4B3 gene showed enhanced B-cell production. 29 The association of rs1678542/KIF5A variant with MS, uncovered for the first time in this work, was first associated with RA in European populations. 18, 30 The rs1678542/KIF5A is located 194 kb apart from the rs703842/methyltransferase-like protein 1 3 0 UTR with a linkage disequilibrium r 2 of 0.184. The latter polymorphism is the most strongly associated SNP with MS in the locus in the GWAS carried out by the Australia and New Zealand Multiple Sclerosis Genetics Consortium. 7 A candidate gene study by the T1D Genetics Consortium also provides evidence of association of this region with T1D. 31 As suggested in the Australia and New Zealand Multiple Sclerosis Genetics Consortium work, 7 assuming a common causal autoimmune susceptibility gene underlying these associations, the strongest candidate gene would be CYP27B1; however, a fine mapping of the region will be required to assign the actual causal gene in all of these diseases.
The rs2812378 positioned 113 nucleotides downstream from the CCL21 gene were also associated with MS (P ¼ 0.047, OR ¼ 0.92, 95% CI ¼ 0.85-1.00). However, it did not withstand correction for multiple testing, and the risk allele obtained in the present study was contrary to the one reported in the original RA study. 18 We observed a lack of association of IL1A, BANK1, ERAP1 (ARTS1), FAM167A-BLK, CCL21, PTPN2, STEAP1, HERC1 and STAT2 variants with MS. The STEAP and HERC1 variants have been associated with MS in a recent GWAS carried out by the Wellcome Trust Case-Control Consortium based on 12 374 non-synonymous SNPs, 22 but were not validated in our sample set. This discrepancy probably reflects a spurious association in the original GWAS. In Table 3 , we have summarized data from different well-powered studies carried out in different population and diseases. It is interesting to note that KIF5A, SH2B3 and CD226 have been found to be associated with most of the studied diseases that suggest their involvement in the basic mechanisms of immunopathologies.
The confirmation of the common and specific associated genes in the different immune-mediated diseases will be crucial in future attempts at shaping the contribution of each pathway to the different disorders and the identification of novel therapies. 00 1.05 1.10 1.15 1.20 1.26 1.32 1 
